Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ
Menée en Angleterre à partir de données 1990-2018 portant sur 27 543 patientes atteintes d'un carcinome canalaire in situ détecté hors du programme de dépistage organisé, cette étude évalue le risque à long terme de développer un cancer du sein invasif et la mortalité spécifique
Is it time for risk based screening and follow-up after a ductal carcinoma in situ diagnosis? Breast cancer screening began in the 1990s, with the aim of detecting invasive breast cancer early and reducing breast cancer deaths.1 Rates of breast cancer deaths have declined over recent decades due to a combination of better systemic treatments, increased awareness, and screening.234 However, since the introduction of screening, incidence of ductal carcinoma in situ (known as DCIS) has increased substantially, accompanied by growing concerns about overdiagnosis and overtreatment.567 Moreover, a recent meta-analysis of randomised trials evaluating cancer screening programmes questioned the net benefit of screening in reducing cancer mortality